Dinh Fortifies InMed’s Development Expertise in Dermatology and Drug Delivery
VANCOUVER, March 6, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today the addition of Dr. Steven M. Dinh to its Scientific Advisory Board.
Dr. Dinh brings more than 30 years of pharmaceutical and biotech executive leadership to InMed, with proven success in developing and commercializing dermal pharmaceutical products by applying innovative drug delivery technologies. His accomplishments in pharmaceutical product development and drug delivery technology innovations have resulted in over 22 issued U.S. patents, 44 published patent applications, 6 NDA approvals and the successful commercialization of 9 products to serve the unmet needs of patients.Â Dr. Dinh currently serves on the Editorial Board of Therapeutic Delivery.Â In addition, Dr. Dinh is a Fellow of the American Association of Pharmaceutical Scientists, and a Fellow of the American Institute for Medical and Biological Engineering.Â He received his doctoral degree from the Massachusetts Institute of Technology.
Eric A. Adams, President and Chief Executive Officer of InMed, commented “As we approach human trials with INM-750 for the treatment of Epidermolysis Bullosa (“EB”), Dr. Dinh’s experience in the development of dermatology-focused therapeutics, with a true expertise in drug delivery, will be a highly value-added skill set for InMed.” Â Mr. Adams added, “he will be instrumental in helping our scientific staff transition the program from pre-clinical development to being on the doorstep of our first human trials.” Â Mr. Adam’s concluded, “We are pleased to add Dr. Dinh to our Scientific Advisory Board.”
“I’m sincerely impressed with InMed’s science-rich R&D pipeline and platform,” commented Dr. Dinh. “Clearly, EB is a devastating disease, and I believe InMed’s cannabinoid-focused scientific approach is novel, differentiated and promising. I’m looking forward to working closely with InMed’s world class teams in advancing INM-750 through clinical development to regulatory approval.”
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements”Â (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: Dr. Dinh joining InMed’s Scientific Advisory Board; conducting human trials for INM-750; developing novel formulations for drug candidates; and the expected fundamental value drivers of the Company.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Dr. Dinh’s continued availability; continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: Dr. Dinh may become unwilling or unable to serve on InMed’s Scientific Advisory Board; clinical trials may not proceed as anticipated; economic or market conditions may worsen; and InMed’s proprietary biosynthesis manufacturing process and drug development programs may not deliver the expected level of results nor become the fundamental value drivers of the Company. A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE InMed Pharmaceuticals Inc.